Cargando…

Ten years of biosimilar recombinant human growth hormone in Europe

Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years. With the expiration of patent exclusivity for the first wave of rhGH products and other biopharmaceuticals, the opportunity emerged for the development of biosimilar medicines. A biosimilar is defined by the Eur...

Descripción completa

Detalles Bibliográficos
Autor principal:	Saenger, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439961/ https://www.ncbi.nlm.nih.gov/pubmed/28553081 http://dx.doi.org/10.2147/DDDT.S130317

Ejemplares similares

Current Status of Biosimilar Growth Hormone
por: Saenger, Paul
Publicado: (2009)

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
por: Schiestl, Martin, et al.
Publicado: (2017)

Ten years’ clinical experience with biosimilar human growth hormone: a review of efficacy data
por: López-Siguero, Juan Pedro, et al.
Publicado: (2017)

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data
por: Borrás Pérez, Maria Victoria, et al.
Publicado: (2017)

Introduction of biosimilar insulins in Europe
por: Davies, M., et al.
Publicado: (2017)

Long‐acting growth hormone in 2022
por: Steiner, Margaret, et al.
Publicado: (2023)

Genetic factors associated with small for gestational age birth and the use of human growth hormone in treating the disorder
por: Saenger, Paul, et al.
Publicado: (2012)

Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
por: Francescon, Sara, et al.
Publicado: (2016)

Efficacy and Safety of Biosimilar Growth Hormone in Indian Children
por: Khadilkar, Vaman, et al.
Publicado: (2018)

Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
por: Rashid, Nazia, et al.
Publicado: (2014)

Policies for biosimilar uptake in Europe: An overview
por: Moorkens, Evelien, et al.
Publicado: (2017)

An update on the clinical evidence that supports biosimilar approvals in Europe
por: Mielke, Johanna, et al.
Publicado: (2018)

Erratum to: Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System
por: Rashid, Nazia, et al.
Publicado: (2014)

Recombinant human growth hormone in the treatment of Turner syndrome
por: Spiliotis, Bessie E
Publicado: (2008)

Key drivers for market penetration of biosimilars in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2017)

Long acting growth hormone (LAGH), an update
por: Grillo, Margaret Steiner, et al.
Publicado: (2023)

Sustainability of Biosimilars in Europe: A Delphi Panel Consensus with Systematic Literature Review
por: Vulto, Arnold G., et al.
Publicado: (2020)

Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children
por: Hou, Ling, et al.
Publicado: (2015)

Ten-year use of recombinant parathyroid hormone for the treatment of hypoparathyroidism in a boy with partial Jacobsen syndrome
por: Dayal, Devi, et al.
Publicado: (2020)

Ten years of MRSA surveillance in Switzerland: similarities and differences with Europe
por: Olearo, F, et al.
Publicado: (2015)

Biosimilars: the process is the product. The example of recombinant streptokinase
por: Thelwell, C, et al.
Publicado: (2014)

A Follow-up Study to Monitor Adult Height Among Spanish Children with Growth Hormone Deficiency Who Received Biosimilar Human Recombinant Growth Hormone (Omnitrope(®)) During a Phase III Clinical Trial
por: Borrás Pérez, Victoria, et al.
Publicado: (2015)

Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: results from a two-center usability study
por: Rapaport, Robert, et al.
Publicado: (2013)

Risk of cancer in patients treated with recombinant human growth hormone in childhood
por: Cianfarani, Stefano
Publicado: (2019)

The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B
por: Joung, Young Hee, et al.
Publicado: (2016)

Efficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar(®) in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical Trial
por: TABATABAEI-MALAZY, Ozra, et al.
Publicado: (2018)

Three years of growth hormone therapy in children born small for gestational age: results from the ANSWER Program
por: Rapaport, Robert, et al.
Publicado: (2018)

Respiratory viruses dynamics and interactions: ten years of surveillance in central Europe
por: Horemheb-Rubio, Gibran, et al.
Publicado: (2022)

ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR BIOSIMILARS IN OPHTHALMOLOGY
por: Kaiser, Peter K., et al.
Publicado: (2022)

Ten years with biosimilar rhGH in clinical practice in Sweden – experience from the prospective PATRO children and adult studies
por: Lundberg, Elena, et al.
Publicado: (2020)

Human Recombinant FSH and Its Biosimilars: Clinical Efficacy, Safety, and Cost-Effectiveness in Controlled Ovarian Stimulation for In Vitro Fertilization
por: Bergandi, Loredana, et al.
Publicado: (2020)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Purification Process of a Recombinant Human Follicle Stimulating Hormone Biosimilar (Primapur(®)) to Yield a Pharmaceutical Product with High Batch-to-Batch Consistency
por: Sinegubova, Maria, et al.
Publicado: (2022)

An examination of the effects of different doses of recombinant human growth hormone on children with growth hormone deficiency
por: XUE, YING, et al.
Publicado: (2016)

Effect of Vitamin D Combined with Recombinant Human Growth Hormone in Children with Growth Hormone Deficiency
por: Wang, Pingping, et al.
Publicado: (2022)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

The Promise and Challenges of Determining Recombinant Bovine Growth Hormone in Milk
por: Raux, Axel, et al.
Publicado: (2022)

Switching From Originator to Biosimilar Human Growth Hormone Using Dialogue Teamwork: Single-Center Experience From Sweden
por: Flodmark, Carl-Erik, et al.
Publicado: (2013)

Ten Years of EWAS
por: Wei, Siyu, et al.
Publicado: (2021)

Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?
por: Mysler, Eduardo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j337u5lde30o114gforaf3pl42